MedTrace Logo

A Study to Assess Safety and Improvement in Skin Barrier After Using 2 Facial Sunscreens in Adults With Sensitive Skin

NCT06243627 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-02-06

No results posted yet for this study

Summary

The purpose of this trial is to evaluate 1) the dermatological tolerability of 2 facial sunscreens after 21 (+2) days of use under normal conditions on the half face by adult subjects with sensitive skin, 2) Compare the efficacy of investigational products (IPs) after 21 (+2) days of use in adult subjects with sensitive skin, under dermatological supervision through the following evaluations: the transepidermal water loss in the nasolabial region; the sensory perception of the subjects using the sensory perception questionnaire, after 21 (+2) days of use under normal conditions; the sensitivity of the subjects' skin after the first application of each product using a questionnaire on the perception of signs of discomfort.

Conditions

  • Healthy

Interventions

OTHER

Sunscreen C Color 2.0 SPF 70

Sunscreen C color 2.0 SPF 70 will be applied topically on half of the face.

OTHER

Sunscreen C Color 3.0 SPF 70

Sunscreen C color 3.0 SPF 70 will be applied topically on half of the face.

OTHER

Sunscreen M Very Light SPF 50

Sunscreen M very light SPF 50 will be applied topically on half of the face.

OTHER

Sunscreen M Golden Color SPF 50

Sunscreen M golden color SPF 50 will be applied topically on half of the face.

Sponsors & Collaborators

  • Johnson & Johnson Consumer Inc. (J&JCI)

    lead INDUSTRY

Principal Investigators

  • Gabrielli Brianezi · Johnson & Johnson Consumer Inc. (J&JCI)

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-27
Primary Completion
2023-11-30
Completion
2023-12-11

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06243627 on ClinicalTrials.gov